month 9 (Figure 3); no significant change of RF-IgM was observed (Figure 4).

Conclusion: The results of the study suggest that both bDMARDs reduced significantly the disease activity in RA patients. The treatment with both drugs was associated with a significant reduction of SAA. However only RTX treatment affected significantly the production of disease specific autoantibodies. Long-term observation is necessary to assess a reliable effect of bDMARDs on the production of marker autoantibodies in association with the disease activity.


Background: Fibrocytes are circulating cells with both myeloid and hematopoietic properties. They home in tissues with active inflammation, where they differentiate into mature fibrocytes that are involved in several inflammatory pathways. One complication of Rheumatoid Arthritis (RA) is Interstitial Lung Disease (ILD) resulting in high mortality and with limited treatment options. Fibrocyte levels are elevated in RA patients compared with healthy individuals and further increased in RA patients with signs of ILD (reduced diffusion capacity) and in patients with idiopathic lung fibrosis (IPF) or scleroderma. Thus, fibrocytes have been proposed as a future treatment target.

Objectives: We investigate the effect of corticosteroids, conventional Disease Modifying Anti Rheumatic Drugs (cDMARDs) and biological DMARDs (bDMARDs) on the in vitro differentiation of isolated peripheral blood mononuclear cells (PBMCs) into mature fibrocytes.

Methods: 10 participants were included (five patients with RA and five healthy controls). Information on current medication, sex, age, serology and disease activity were collected. PBMCs were isolated and cultured for 5 days in four wells per drug. Drugs included prednisolone, cDMARD (Methotrexate, Sulfasalasine, Hydroxychloroquine) and bDMARD (Inflectra, Etanecept, Tocilizumab, Adalimumab, Abatacept, Rituximab), and control wells with no drugs.

Results: Overall, abatacept and prednisolone significantly suppressed differentiation of PBMC into fibrocytes compared to control wells, see Figure 1 (p=0.02 and p<0.01, respectively) (n=10). The reductive effect of Abatacept was significant among RA patients (p=0.009 and) but not among healthy subjects. In overall analysis (n=10), Abatacept reduced fibrocyte levels with an average of 44% overall and in the RA group 71% compared to control wells. Tocilizumab reduced the fibrocyte count with 63% overall and 45% in the RA group, although not significant (p=0.07 and p=0.06 respectively).

Conclusion: Abatacept and prednisolone suppress the differentiation of mononuclear cells to mature fibrocytes in vitro in RA patients and data indicating a similar effect of Tocilizumab. Prednisolone are used in the treatment of RA-ILD but has a marked toxicity, so new treatment modalities are desirable. Our findings are in line with the fact that fibrocytes have the receptors targeted by abatacept, furthermore recent scleroderma research has shown Abatacept to reduce fibrocyte levels in vitro and Tocilizumab to potentially reduce lung and skin affection( 1, 2) Further research using abatacept and tocilizumab to target fibrocytes are needed in order investigate the treatment potential of these drugs in RA-ILD.
**REFERENCES**


**Disclosure of Interests:** None declared


**AB0415**

**SURVIVAL OF BIOLOGIC AGENTS WITHIN A COHORT OF GREEK PATIENTS WITH RHEUMATOID ARTHRITIS. REAL WORLD DATA.**

Olga Katsouli1, Georgia Liantinioti1, Panagiota Katsouli1, Mary Pappa1, Markus Patsouras1, Theodoros Angelopoulos2, Sotiris Roussos3, VLACHOYIANNOPoulos PANAYIOTIS1. 1Medical School National and Kapodistrian University of Athens, Department of Pathophysiology, Athens, Greece; 2Medical School National and Kapodistrian University of Athens, Athens, Greece; 3Medical School National and Kapodistrian University of Athens, Hygiene, Epidemiology and Medical Statistics, Athens, Greece

**Background:** Rheumatoid arthritis (RA) is treated successfully with biologic disease-modifying anti-rheumatic drugs (bDMARDs). However, a significant withdrawal rate, due to non-responsiveness or toxicity, remains a major barrier for their long-term use.

**Objectives:** To determine the withdrawal rate of the first bDMARD in a large cohort of RA patients due either, to non-responsiveness or toxicity.

**Methods:** In this study, we included retrospectively 220 patients from our outpatient clinic. The following bDMARDs were evaluated: Etanercept (n=66 patients), Adalimumab (n=61 patients), Infliximab (n=70 patients), Rituximab (n=6 patients) and others, such as Certolizumab pegol, Golimumab, Tocilizumab, Anakinra and Abatacept (n=17 patients). Disease activity was regularly measured by DAS-28 until the end of follow up. Kaplan-Meier plots were performed to examine the withdrawal rate of each biologic agent. Severity of AEs was classified according to the Common Terminology Criteria for Adverse Events (CTCAE, version 4.03).

**Results:** A total of 220 patients (49 men, 171 women) were included in the analysis. The most frequently used first-line bDMARDs were Infliximab (31.8%), Etanercept (30%) and Adalimumab (27.7%). The median time to start with the first bDMARD was 15 months (Q1:8, Q3:40.5). Taking all bDMARDs as a whole, 126 patients (57.2%) discontinued the first bDMARD, either due to AEs(n=86, 52.38%), or loss of efficacy (n=60,47.62%) after a follow-up of 167 months. However the most withdrawals (53.18%) occurred within the first 60 months of follow up. Mean initial and final DAS-28 were: for those who continued treatment due to AEs 4.96±1.33(95%CI, 4.64-5.28) and 3.43±1.47(95%CI, 3.09-3.89), respectively, for those who discontinued due to AE 5.04±1.37(95%CI, 4.70-5.39) and 4.91±1.27(95%CI, 4.59-5.32), respectively, for those who achieve 4.79±1.55(95%CI, 4.47-5.10) and 2.63±1.06(95%CI, 2.41-2.84), respectively. Differences in survival among bDMARDs are attributed to their AEs and not to their efficacy. As far as the AEs are concerned, infections constituted the majority of cases (n=23, 34.8%), from which 34.8% needed hospitalization (CTCAE 3-4). The percentage of 12.1% of AEs is attributed to cancer cases, while allergic reactions counted for 31.8% of them. Survival of Etanercept within our cohort was significantly longer than those of other bDMARDs.

**Conclusion:** Biologic agents are important drugs in our armamentarium to combat RA. However nearly 50% of patients discontinue these agents after 60 months of treatment due either to AEs or inefficacy. Differences in survival of bDMARDs were associated not to their inefficacy, but to their AEs. Choosing the right drug for the right patient is a matter of advanced research involving a better understanding of the pathways of inflammation and specific biomarker selection.

**REFERENCES**
